New cancer drug LY3200882 enters early human safety testing
NCT ID NCT02937272
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 31 times
Summary
This early-phase study tests the safety of a new drug called LY3200882 in 223 adults with solid tumors. Researchers aim to find a safe dose and check if the drug can shrink tumors. The study is not yet recruiting and is actively ongoing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Lille
Lille, 59037, France
-
Calvary Mater Newcastle
Newcastle, New South Wales, 2298, Australia
-
Charité Campus Virchow-Klinikum
Berlin, 12203, Germany
-
Greenslopes Private Hospital
Greenslopes, Queensland, 4120, Australia
-
Gustave Roussy
Villejuif, 94805, France
-
Hopital Saint-Louis
Paris, Cedex 10, 75475, France
-
Hospital Clínico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Istituto Clinico Humanitas
Rozzano, Milano, 20089, Italy
-
National Cancer Center Hospital
Chuo-Ku, Tokyo, 104-0045, Japan
-
Ospedale Policlinico Giambattista Rossi, Borgo Roma
Verona, 37134, Italy
-
Princess Margaret Hospital (Ontario)
Lai Chi Kok, Kowloon, Canada
-
St Vincent's Hospital Sydney
Sydney, New South Wales, 2010, Australia
-
University of Louisville
Louisville, Kentucky, 40202, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universitätsklinikum Würzburg A. ö. R.
Würzburg, Bavaria, 97080, Germany
-
Weill Cornell Medical College
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.